SYNTHESIS OF "9-DEAZAADENOSINE"; A NEW CYTOTOXIC C-NUCLEOSIDE ISOSTERE OF ADENOSINE¹

Mu-Ill Lim and Robert S. Klein* Laboratory of Organic Chemistry, Sloan-Kettering Institute Memorial Sloan-Kettering Cancer Center, New York, N. Y. 10021


The discovery that a nucleoside antibiotic, tubercidin (4-amino-7-(β -<u>D</u>-ribofuranosyl)pyrrolo[2,3-<u>d</u>]pyrimidine or 7-deazaadenosine) is a powerful antibacterial, antifungal and cytotoxic analog of adenosine² spurred interest in the synthesis of several structurally related deazapurine nucleosides.³ Of the four possible monodeazaadenosines, tubercidin,⁴ l-deaza-⁵ and 3-deazaadenosine⁶ have already been synthesized. We now wish to report the synthesis of the last remaining member of this series, viz., 9-deazaadenosine, a new synthetic pyrrolo[3,2-<u>d</u>]pyrimidine C-nucleoside of exceptional cytotoxicity to several lines of mouse and human leukemias (see below).


We have reported recently the synthesis of $7-(\beta-\underline{D}-ribofuranosyl)-4-oxo-3H,5H - pyrrolo-[3,2-\underline{d}]$ pyrimidine (9-deazainosine) by a two-step conversion of a 4-ribosylated 3-amino-2-carboalkoxy pyrrole.⁷ Synthesis of this key intermediate relied upon ring-closure of an N-benzyl- β -enaminoacrylonitrile. While final removal of the N-benzyl blocking group could be readily achieved on a small scale by treatment with sodium naphthylide in tetrahydrofuran at 20° , ⁷,⁸ its removal by catalytic hydrogenolysis under milder conditions was not successful. The synthesis of 9-deazaadenosine described below utilizes instead a carboalkoxy group for protection of enamine 3 and should be of general applicability to the large-scale preparation of other structurally related 9-deazapurine C-nucleosides.


The intermediate $2-(\underline{D}-ribofuranosyl)-2$ -formylacetonitrile 2,7 readily obtained from 3dimethylaminoacrylonitrile⁹ 1 by mild acid hydrolysis, was converted to enamine 3 (81.5% from 1) by condensation with aminoacetonitrile hydrochloride (1.3 equiv.) in the presence of sodium acetate (1.5 equiv.) in aqueous methanol (25°, 20 hr). Our earlier studies¹⁰ had indicated that blocking of the enamino-NH group of 3 was essential for effective ring-closure to the desired pyrrole. Such blocking was carried out by reaction of 3 with ethyl chloroformate (1.5 equiv.) and 1,5-diazabicyclo[4,3,0]nonene-5 (DBN, 2 equiv.) in methylene chloride


25



















 $(0^{\text{C}}, 1 \text{ hr})$ to afford carbamate intermediate 4 as a mixture of epimers. Cyclization to pyrrole 5 could be carried out without isolation of this intermediate by treatment of the reaction mixture containing 4 with one additional equivalent of DBN (25[°], 20 hr) to give N-carboethoxypyrrole 5 (84% overall yield from 3) as a mixture of α - β isomers.

Removal of the carboethoxy group at this stage was readily carried out by treatment of 5 with sodium carbonate (0.1 equiv.) in methanol (25° , 50 min) to give the desired unblocked β_{\neg} and α -3-amino-2-cyanopyrroles 6 (m.p. 170-172° from ethyl acetate-ethyl ether) and 7 (m.p. 176°, dec from acetone-hexane), respectively (85% overall yield from 3, $\beta/\alpha \sim 5/2$). These were separated by silica gel column chromatography¹¹ (toluene-ethyl acetate, 8:1) and identified by their NMR spectra.¹²

Although the α - and β -epimers of each of $\frac{4}{2}$ and $\frac{5}{5}$ can be readily separated and have been fully characterized,¹² it was found more convenient for large-scale preparative work to delete isolation of the desired β -isomer until completion of the decarboethoxylation step as we describe above. It is noteworthy that conversion of the isolated β -isomer of $\frac{4}{2}$ to $\frac{5}{2}$ and finally to 6 could be carried out without detectable epimerization at C-1'.

Treatment of 6 with formamidine acetate¹³ (3 equiv.) in boiling ethanol (5 hr) afforded pyrrolopyrimidine 8 in 93.6% yield; H¹NMR (CDCl₃): δ 1.31, 1.51 (2s, 3H each, C(CH₃)₂), 3.37 (m, 2H, H-5', H-5"), 4.26 (m, 1H, H-4'), 4.77 (m, 1H, H-3'), 4.95 (m, 1H, H-2'), 5.22 (d, 1H, H-1', J = 4.3 Hz), 6.62 (bs, 2H, NH₂, exch. with D₂O), 7.17-7.39 (m, 16H, trityl and H-6), 7.70 (s, 1H, H-2). By an identical procedure, the corresponding α -isomer 7 was converted to 10; H¹NMR (CDCl₃): δ 1.28, 1.47 (2s, 3H each, C(CH₃)₂), 3.27 (m, 2H, H-5', H-5"), 4.36 (t, 1H, H-4'), 4.70-4.91 (m, 2H, H-2', H-3'), 5.49 (d, 1H, H-1', J = 3.1 Hz), 6.49 (bs, 2H, NH₂, exch. with D₂O), 7.21-7.50 (m, 16H, trityl and H-6), 8.16 (s, 1H, H-2).

Treatment of 8 with 12% HC1/MeOH (25^o, 2 hr) afforded unblocked 9-deazaadenosine 9 which crystallized directly from the reaction mixture (75%). Recrystallization from ethanol afforded an analytically pure sample of the hydrochloride salt, m.p. 179-183^o; H¹NMR (DMSO-d₆) δ 3.64 (d, 2H, H-5' and 5", J = 3, 1 Hz), 3.91-3.99 (m, 3H, H-2',3',4'), 4.88 (d, 1H, H-1', J = 6.4 Hz), 7.87 (d, 1H, H-6, J = 2.7 Hz, singlet with D₂O), 8.51 (s, 1H, H-2), 8.93 (bs, 2H, NH₂, exch. with D₂O), 12.16 (bs, 1H, NH, exch. with D₂O). Similarly, unblocking of the α -isomer 10 afforded the corresponding α -isomer of 9-deazaadenosine obtained as a hygroscopic solid; H¹NMR (DMSO-d6) δ 3.49-3.60 (m, 2H, H-5' and 5"), 4.06-4.21 (m, 3H, H-2',3',4'), 5.15 (d, 1H, H-1', J = 3.1 Hz), 7.81 (d, 1H, H-6, J = 2.7 Hz, singlet with D₂O), 8.47 (s, 1H, H-2), 9.02 (bs, 2H, NH₂, exch. with D₂O), 12.88 (bs, 1H, NH, exch. with D₂O).

The preliminary <u>in vitro</u> data¹⁴ summarized in Table I indicate that 9-deazaadenosine has pronounced growth inhibitory activity against several mouse and human leukemic cell lines.

J	AB	LE	Ι

In Vitro Activity (ID₅₀ in μ g/ml) of 9-Deazaadenosine¹⁴

Mouse leukemia	P815	L5178Y	L1210	Human leukemia	HL60	K562	RPMI 8402
<u>cell lines</u>				<u>cell lines</u>			
ID ₅₀	0.001	0.002	0.0008	ID ₅₀	0.0007	0.002	0.002

<u>Acknowledgements</u>. We are indebted to Dr. Jack J. Fox for his continued interest, to Dr. Brian A. Otter for useful discussions, to Ms. Iris Wempen for the preparation of <u>1</u>, to Mr. Marvin Olsen for recording the NMR spectra and to the Department of Mass Spectrometric Biotechnology Resource at The Rockefeller University, New York (NIH grant RR-862) for mass spectral measurements.¹⁵

References and Notes

- This investigation was supported by funds from the National Cancer Institute, DHEW (Grants CA-08748, 18856 and 24634).
- a) R. J. Suhadolnik, "Nucleoside Antibiotics," Wiley-Interscience, New York, N. Y., 1970, Chapter 8, p. 315; (b) ibid., "Nucleosides as Biological Probes," Wiley-Interscience, New York, N. Y., 1979, Chapter 3, p. 158.
- 3. A. Bloch, Ann. N. Y. Acad. Sci., 255, 576 (1975), and references therein.
- 4. R. L. Tolman, R. K. Robins and L. B. Townsend, J. Heterocycl. Chem., 4, 230 (1967).
- 5. a) P. C. Jain, S. K. Chatterjee and N. Anand, Ind. J. Chem., <u>4</u>, 403 (1966); (b)
 K. B. De Roos and C. A. Salemink, Rec. Trav. Chim. Pays bas, <u>90</u>, 654 (1971); (c)
 T. Itoh, S. Kitano and Y. Mizuno, J. Heterocycl. Chem., <u>9</u>, 465 (1972).
- 6. R. J. Rousseau, L. B. Townsend and R. K. Robins, Biochemistry 5, 756 (1966).
- 7. M-I. Lim, R. S. Klein and J. J. Fox, Tetrahedron Lett., 1013 (1980).
- 8. K. D. Philips and J. P. Horwitz, J. Org. Chem., <u>40</u>, 1856 (1975).
- 9. S. De Bernardo and M. Weigele, J. Org. Chem., <u>42</u>, 109 (1977).
- 10. M-I. Lim, R. S. Klein and J. J. Fox, J. Org. Chem., 44, 3826 (1979).
- 11. W. C. Still, M. Kahn and A. Mitra, J. Org. Chem., <u>43</u>, 2923 (1978).
- 12. Criteria for determining the epimeric configuration at C-1 of several α and β Cnucleoside pairs have been discussed in the following paper and in references therein: S. Y-K. Tam, R. S. Klein, H. G. de las Heras and J. J. Fox, J. Org. Chem., <u>44</u>, 4854 (1979)
- For a review, see E. C. Taylor and A. McKillop, "The Chemistry of Cyclic Enaminonitriles and O-Aminotriles" <u>in</u> Advances in Organic Chemistry, Vol. 7, Wiley-Interscience, New York, N. Y., 1970, Chapter VIII, p. 243.
- 14. The authors are indebted to Dr. Joseph H. Burchenal of this Institute for the communication of these results.
- 15. All new compounds were characterized by their NMR spectra and elemental analysis supported in some instances by mass spectroscopic data.

(Received in USA 22 August 1980)